Tufts CSDD Vendor Qualification Survey
The Tufts Center for the Study of Drug Development is gathering new benchmark data on the vendor qualification process including the time, cost, and resources required to qualify contract service and technology vendors.
The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting an important new empirical study looking at the time and cost of the vendor qualification assessment process to all stakeholders involved—including those who issue RFIs/RFPs and conduct qualifications and those who respond to them. Tufts CSDD is hoping to gather a large robust global response. To complete a survey, please choose the appropriate questionnaire:
- Click this link if your organization conducts qualifications of clinical trial service Providers or third-party vendors: Sponsor/CRO Survey
- Click this link if your organization hosts qualification requests from other Providers or Sponsors: Vendor/CRO Survey
- Click this link if you are an investigative site that hosts qualification requests: Site Survey
All responses are confidential and will only be presented in the aggregate - no individual or organization will be identified.
Tufts CSDD will send you a summary report of the results as a thank you for your participation.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
